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Clinicians 
who prescribe 
testosterone 
therapy should 
monitor 
hematocrit and 
bone mineral 
density.
 How should we monitor 
men receiving testosterone 
replacement therapy? 
EVIDENCE-BASED ANSWER
A monitor hematocrit and bone mineral density (BMD) (strength of 
recommendation [SOR]: B, meta-analysis of 
no n−patient-oriented outcomes). Monitor-
ing prostate-specifi c antigen (PSA), perform-
ing prostate digital rectal examination, and 
observing symptom response to testosterone 
are also recommended, although direct evi-
dence is lacking (SOR: C, consensus opinion). 
Monitoring lipid levels is unnecessary 
(SOR: A, based on several meta-analyses), 
as is monitoring testosterone levels (SOR C,
consensus opinion). Unless the patient is tak-
ing oral testosterone, no evidence exists for 
or against monitoring liver function (SOR: C,
consensus opinion).
Evidence summary
A hematocrit >50% is the most frequent tes-
tosterone-related adverse event in clinical 
trials. In a meta-analysis of 19 randomized 
controlled trials (RCTs)—with a total of 1084 
subjects, 651 on testosterone, 433 on pla-
cebo—testosterone-treated men were nearly 
4 times as likely as placebo-treated men to 
have a hematocrit >50% (odds ratio [OR]=3.67; 
95% confi dence interval [CI], 1.82-7.51; num-
ber needed to harm [NNH]=14).1 Th e clinical 
signifi cance of the increase is unclear. 
Increased BMD at lumbar spine
A meta-analysis of 5 RCTs with a total of 264 
subjects (135 on testosterone, 129 on pla-
cebo) demonstrated a 3.7% (95% CI, 1.0%-
6.4%) absolute increase over baseline in 
lumbar spine BMD after ≥12 to 36 months 
of treatment.2 However, pooled eff ects on 
lumbar spine BMD across all studies failed 
to reach statistical signifi cance because of 
diff erences in baseline bone density among 
subjects (BMD increase=0.03 g/cm2; 95% CI, 
0-0.07). 
No studies in this meta-analysis showed 
statistically signifi cant improvement in BMD 
at the femoral neck. We found no studies that 
demonstrated reduced fracture risk in pa-
tients taking testosterone replacement.
No correlation between testosterone 
therapy and cancer
Although testosterone can stimulate the growth 
of locally advanced and metastatic prostate can-
cer,3 at least 16 longitudinal studies have failed 
to show any correlation between testosterone 
replacement and the development of malig-
nancy.4 In the previously mentioned meta-
analysis of 19 RCTs, rates of prostate cancer, PSA 
>4 ng/mL, increase in International Prostate 
Symptom Score (IPSS) >4, and prostate biopsies 
were all numerically higher in testosterone-treat-
ed men, but the diff erences between the testos-
terone and placebo groups weren’t statistically 
signifi cant.1 Moreover, the average serum PSA 
level in the testosterone-treated men increased 
only 0.3 ng/mL from a baseline of 1.3 ng/mL.
 Testosterone lowers total cholesterol
A meta-analysis of 30 RCTs (1642 men, 808 on 
testosterone therapy, 834 on placebo) that as-
sessed testosterone’s eff ect on lipid levels found 
that testosterone reduced total cholesterol lev-
els by 16 mg/dL (95% CI, 6-26 mg/dL); eff ects 
on all other lipid fractions weren’t signifi cant.5 
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A second meta-analysis of 16 RCTs 
(578 men, 320 on testosterone therapy, 258 
on placebo) similarly showed that testos-
terone lowered total cholesterol levels by 
8 mg/dL (95% CI, 4-14 mg/dL) and that its 
eff ects on other lipid fractions weren’t sig-
nifi cant.2 Th e previously mentioned meta-
analyses of 19 and 30 RCTs found no signifi cant 
diff erence in cardiovascular events between 
testosterone- and placebo-treated groups.1,5
Optimal testosterone level is unknown
Data are inadequate to determine the optimal se-
rum level of testosterone for effi  cacy and safety.3 
Expert opinion suggests that because therapy is 
empiric, monitoring clinical response may help 
guide treatment more than testosterone level.6
What about the liver? 
Oral testosterone can be associated with 
hepatotoxicity; it is seldom used in the United 
States. Liver monitoring is unnecessary for 
patients receiving testosterone by injection, 
patch, or transbuccal tablet.7,8
Recommendations 
Consensus guidelines for monitoring men 
on testosterone therapy overlap consider-
ably with regard to monitoring clinical ef-
fectiveness, prostate measures, hematocrit, 
and BMD (TABLE).3,6,9,10 Assessing testoster-
one level is recommended, with the aim 
of achieving levels in the mid-normal 
range.10                            JFP
 
Organization First follow-up DRE PSA test
Testosterone
levels Hematocrit BMD Lipids
American 
Association 
of Clinical 
Endocrinologists9
q 3-4 mo in 
fi rst year
q 6-12 mo Annually q 6 mo 
x 3, then 
annually
q 1-2 y At 6-12 
wk, then 
annually
American Society 
for Reproductive 
Medicine6
At 2-3 mo In fi rst 2-3 mo At 3 and 6 
mo, then 
annually
At 3 and 6 
mo, then 
annually
At 3 and 6 
mo, then 
annually
At 2 y
The Endocrine 
Society10
At 3 mo, then 
annually
At 3 mo, then 
per routine 
guidelines
At 3 mo, then 
per routine 
guidelines
At 3 mo At 3 mo, 
then 
annually
At 1-2 y
European 
Association of 
Urology3
At 3 mo At 3 and 6 mo, 
then annually
At 3 and 6 
mo, then 
annually
At 3 mo, 
then 
annually
q 1-2 y
BMD, bone mineral density; DRE, digital rectal exam; PSA, prostate-specifi c antigen.
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